Semaglutide

Nature medicine · 2024

Researchers studied the long-term effects of semaglutide, a medication for weight loss, in adults with obesity but without diabetes. They found that participants lost an average of 10.2% of their body weight over 208 weeks, and this weight loss was maintained for up to four years.

• Participants taking semaglutide experienced significant reductions in weight, waist circumference, and waist-to-height ratio compared to those on a placebo.
• Weight loss was consistent across different sexes, races, and body sizes.
• Semaglutide was associated with fewer serious adverse events compared to the placebo group.

Journal of drugs in dermatology : JDD · 2024

Researchers studied the rising popularity of semaglutide medications, Ozempic and Wegovy, for weight loss and the social media phenomenon known as 'Ozempic face.' This term describes the rapid facial weight loss that some users experience, leading to concerns about its effects on appearance. The study highlights the role of dermatologists in advising patients about potential changes in their facial appearance due to weight loss.

• Researchers observed that semaglutide is FDA-approved for chronic weight management in certain patients.
• The term 'Ozempic face' emerged on social media to describe facial changes from rapid weight loss.
• The study emphasizes the need for healthcare professionals to differentiate between natural weight loss effects and potential adverse reactions.

JAMA · 2023

This article explores the use of semaglutide, known as Ozempic and Wegovy, for managing chronic weight issues. Researchers found that these medications can aid in weight loss for individuals struggling with obesity, highlighting their growing popularity and effectiveness in weight management.

• Researchers observed that semaglutide can lead to significant weight loss in individuals with obesity.
• The study highlighted the increasing popularity of Ozempic and Wegovy among those seeking to manage their weight.
• Researchers noted the importance of understanding how these medications work in the context of chronic weight management.

The lancet. Diabetes & endocrinology · 2022

Researchers studied the effects of semaglutide, a weight management medication, in adults from East Asia with obesity, with or without type 2 diabetes. They found that those taking semaglutide experienced significant weight loss and reductions in abdominal fat compared to those receiving a placebo.

• Participants taking semaglutide 2.4 mg lost an average of 13.2% of their body weight over 68 weeks, compared to just 2.1% in the placebo group.
• A higher percentage of participants on semaglutide achieved at least a 5% reduction in body weight compared to those on placebo.
• Semaglutide also led to a significant reduction in abdominal visceral fat, with a 40% decrease in the 2.4 mg group versus 6.9% in the placebo group.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022

Researchers observed that Wegovy, a new weight loss drug containing semaglutide, is effective in promoting weight loss in individuals with obesity and those with type 2 diabetes. The study reviewed data from several clinical trials, showing that semaglutide significantly outperformed placebo and other diabetes medications in reducing weight.

• The STEP trial demonstrated that a higher dose of semaglutide led to significant weight loss in patients with obesity.
• The SUSTAIN and PIONEER trials showed that semaglutide was effective in managing weight and blood sugar levels in individuals with type 2 diabetes.
• Overall, semaglutide received FDA approval for weight loss due to its superior efficacy compared to other treatments.

Journal of the ASEAN Federation of Endocrine Societies · 2022

Researchers found that semaglutide, an injectable medication, can lead to significant weight loss in individuals with obesity who do not have diabetes, showing an average reduction of nearly 12%. However, they also noted an increased risk of gastrointestinal issues and treatment discontinuation in those using semaglutide compared to a placebo.

• Semaglutide resulted in an average weight loss of 11.85% in individuals with obesity without diabetes.
• The study included data from 4 trials with a total of 3,613 participants.
• Participants using semaglutide experienced higher rates of gastrointestinal adverse events and treatment discontinuation compared to those receiving a placebo.

Frontiers in endocrinology · 2021

Researchers reviewed the safety of semaglutide, a medication for type 2 diabetes, which is available in both injectable and oral forms. They found that while semaglutide can cause mild to moderate gastrointestinal issues and may increase the risk of gallbladder disease, no unexpected safety concerns have emerged, and its overall risk/benefit profile is favorable for patients.

• Researchers observed that semaglutide primarily causes mild to moderate gastrointestinal disturbances.
• The review noted an increased risk of gallbladder disease, but no unexpected safety issues were identified.
• Researchers found that the safety profile of semaglutide is similar to other medications in its class, with careful monitoring recommended for certain patients.

JCI insight · 2020

Researchers found that semaglutide, a medication used for diabetes, can lower body weight in rodents by influencing brain pathways related to food intake and preference. The study observed that semaglutide activates specific brain areas without crossing the blood-brain barrier, leading to reduced food consumption without affecting energy expenditure.

• Semaglutide modulated food preferences and reduced food intake in rodents.
• The medication accessed various brain regions involved in appetite control without crossing the blood-brain barrier.
• Activation of certain brain pathways suggests that semaglutide influences how meals are terminated.

Drugs · 2018

This study reviewed the global approval of semaglutide, a medication developed by Novo Nordisk for subcutaneous use. Researchers observed its significance in managing certain health conditions, highlighting its innovative formulation and potential impact on treatment options.

• Researchers observed that semaglutide received its first global approval for subcutaneous administration.
• The study noted the importance of semaglutide in expanding treatment options for specific health conditions.
• Researchers highlighted the innovative formulation of semaglutide as a key advancement in medication delivery.